Indentifying Epigenetic Biomarkers From Peripheral Blood of Osteosarcoma Patients Based on hMe-Seal Technique View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2017-2018

ABSTRACT

hMe-Seal is a low-input whole-genome cell-free 5hmC sequencing method based on selective chemical labeling. It uses β-glucosyltransferase (βGT) to selectively label 5hmC with a biotin via an azide-modified glucose for pull-down of 5hmC-containing DNA fragments for sequencing. After selectively constructing 5hmC library, highthroughput-sequencing will be performed on an Illumina Nextseq-500 instrument. By ways of Rawdata processing, differential loci between Osteosarcoma group and control group will be detected to indentify specific epigenetic biomarkers of Osteosarcoma. Detailed Description The investigator want to enroll 100 osteosarcoma participants initially treated in Musculoskeletal Tumor Center of Peking University People's Hospital(PKUPH). All those participants will follow the chemo-protocol for osteosarcoma in PKUPH.8 ml of peripheral blood would be drawed before each cycle of chemotherapy for further analysis. After definitive surgery, participants will need to take 8ml of peripheral blood every 2 months for 6 months. A total of 6 times of blood drawing will need to be done. In hMe-Seal approach, peripheral blood is collected into EDTA-coated Vacutainers. Plasma is collected from the blood samples after centrifugation at 1 600× g for 10 min at 4 °C and 16 000× g at 10 min at 4 °C. CfDNA is extracted using the Circulating Nucleic Acid Kit(QIAGEN). After that, cfDNA (1-10 ng) is end repaired, 3'-adenylated and ligated to DNA Barcodes using KAPA Hyper Prep Kit (Kapa Biosystems). Ligated DNA is incubated in a solution containing HEPES buffer, UDP-6-N3-Glc and βGT . After that, DBCO-PEG4-biotin is directly added to the reaction mixture. Next, DNA is purified by Micro Bio-Spin 30 Column (Bio-Rad). The purified DNA is incubated with M270 Streptavidin beads (Life Technologies) in specific buffer. The beads are subsequently undergone three 5-min washes each with four kinds of different buffers. All binding and washing are done at room temperature with gentle rotation. Beads are then resuspended in water and amplified with 16 cycles of PCR amplification. The PCR products are purified using AMPure XP beads. Pair-end 38bp sequencing is performed on the NextSeq-500 instrument. More... »

URL

https://clinicaltrials.gov/show/NCT03336554

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "hMe-Seal is a low-input whole-genome cell-free 5hmC sequencing method based on selective chemical labeling. It uses \u03b2-glucosyltransferase (\u03b2GT) to selectively label 5hmC with a biotin via an azide-modified glucose for pull-down of 5hmC-containing DNA fragments for sequencing. After selectively constructing 5hmC library, highthroughput-sequencing will be performed on an Illumina Nextseq-500 instrument. By ways of Rawdata processing, differential loci between Osteosarcoma group and control group will be detected to indentify specific epigenetic biomarkers of Osteosarcoma.\n\nDetailed Description\nThe investigator want to enroll 100 osteosarcoma participants initially treated in Musculoskeletal Tumor Center of Peking University People's Hospital(PKUPH). All those participants will follow the chemo-protocol for osteosarcoma in PKUPH.8 ml of peripheral blood would be drawed before each cycle of chemotherapy for further analysis. After definitive surgery, participants will need to take 8ml of peripheral blood every 2 months for 6 months. A total of 6 times of blood drawing will need to be done. In hMe-Seal approach, peripheral blood is collected into EDTA-coated Vacutainers. Plasma is collected from the blood samples after centrifugation at 1 600\u00d7 g for 10 min at 4 \u00b0C and 16 000\u00d7 g at 10 min at 4 \u00b0C. CfDNA is extracted using the Circulating Nucleic Acid Kit(QIAGEN). After that, cfDNA (1-10 ng) is end repaired, 3'-adenylated and ligated to DNA Barcodes using KAPA Hyper Prep Kit (Kapa Biosystems). Ligated DNA is incubated in a solution containing HEPES buffer, UDP-6-N3-Glc and \u03b2GT . After that, DBCO-PEG4-biotin is directly added to the reaction mixture. Next, DNA is purified by Micro Bio-Spin 30 Column (Bio-Rad). The purified DNA is incubated with M270 Streptavidin beads (Life Technologies) in specific buffer. The beads are subsequently undergone three 5-min washes each with four kinds of different buffers. All binding and washing are done at room temperature with gentle rotation. Beads are then resuspended in water and amplified with 16 cycles of PCR amplification. The PCR products are purified using AMPure XP beads. Pair-end 38bp sequencing is performed on the NextSeq-500 instrument.", 
    "endDate": "2018-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT03336554", 
    "keywords": [
      "epigenetic biomarkers", 
      "peripheral blood", 
      "technique", 
      "sequencing method", 
      "chemical labeling", 
      "glucosyltransferases", 
      "biotin", 
      "glucose", 
      "DNA fragment", 
      "sequencing", 
      "library", 
      "Illumina", 
      "instrument", 
      "processing", 
      "locus", 
      "osteosarcoma", 
      "control group", 
      "Peking University", 
      "protocol", 
      "cycle", 
      "Drug Therapy", 
      "drawing", 
      "seal", 
      "plasma", 
      "blood sample", 
      "centrifugation", 
      "min", 
      "nucleic acid", 
      "DNA barcodes", 
      "biosystems", 
      "DNA", 
      "solution", 
      "buffer", 
      "GLC", 
      "reaction mixture", 
      "micro", 
      "column", 
      "Bio-Rad", 
      "purified DNA", 
      "streptavidin", 
      "bead", 
      "technology", 
      "wash", 
      "binding", 
      "room temperature", 
      "rotation", 
      "water", 
      "PCR amplification", 
      "PCR product", 
      "XPS"
    ], 
    "name": "Indentifying Epigenetic Biomarkers From Peripheral Blood of Osteosarcoma Patients Based on hMe-Seal Technique", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03336554"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00025.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.411634.5", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.170205.1", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.11135.37", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.16753.36", 
        "type": "Organization"
      }
    ], 
    "startDate": "2017-09-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1007/s13277-013-0966-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004216767", 
          "https://doi.org/10.1007/s13277-013-0966-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.27651", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004665337"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/srep17568", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010916831", 
          "https://doi.org/10.1038/srep17568"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0300060514534643", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016778774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-1-4419-0284-9_15", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017083848", 
          "https://doi.org/10.1007/978-1-4419-0284-9_15"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nchem.2064", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021457238", 
          "https://doi.org/10.1038/nchem.2064"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.canep.2015.05.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028431590"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000448705", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033830562"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)30214-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035951195"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jso.23076", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043913930"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/nar/gkh739", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052677568"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077461573", 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03336554"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03336554'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03336554'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03336554'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03336554'


 

This table displays all metadata directly associated to this object as RDF triples.

114 TRIPLES      16 PREDICATES      80 URIs      59 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03336554 schema:about anzsrc-for:3053
2 schema:description hMe-Seal is a low-input whole-genome cell-free 5hmC sequencing method based on selective chemical labeling. It uses β-glucosyltransferase (βGT) to selectively label 5hmC with a biotin via an azide-modified glucose for pull-down of 5hmC-containing DNA fragments for sequencing. After selectively constructing 5hmC library, highthroughput-sequencing will be performed on an Illumina Nextseq-500 instrument. By ways of Rawdata processing, differential loci between Osteosarcoma group and control group will be detected to indentify specific epigenetic biomarkers of Osteosarcoma. Detailed Description The investigator want to enroll 100 osteosarcoma participants initially treated in Musculoskeletal Tumor Center of Peking University People's Hospital(PKUPH). All those participants will follow the chemo-protocol for osteosarcoma in PKUPH.8 ml of peripheral blood would be drawed before each cycle of chemotherapy for further analysis. After definitive surgery, participants will need to take 8ml of peripheral blood every 2 months for 6 months. A total of 6 times of blood drawing will need to be done. In hMe-Seal approach, peripheral blood is collected into EDTA-coated Vacutainers. Plasma is collected from the blood samples after centrifugation at 1 600× g for 10 min at 4 °C and 16 000× g at 10 min at 4 °C. CfDNA is extracted using the Circulating Nucleic Acid Kit(QIAGEN). After that, cfDNA (1-10 ng) is end repaired, 3'-adenylated and ligated to DNA Barcodes using KAPA Hyper Prep Kit (Kapa Biosystems). Ligated DNA is incubated in a solution containing HEPES buffer, UDP-6-N3-Glc and βGT . After that, DBCO-PEG4-biotin is directly added to the reaction mixture. Next, DNA is purified by Micro Bio-Spin 30 Column (Bio-Rad). The purified DNA is incubated with M270 Streptavidin beads (Life Technologies) in specific buffer. The beads are subsequently undergone three 5-min washes each with four kinds of different buffers. All binding and washing are done at room temperature with gentle rotation. Beads are then resuspended in water and amplified with 16 cycles of PCR amplification. The PCR products are purified using AMPure XP beads. Pair-end 38bp sequencing is performed on the NextSeq-500 instrument.
3 schema:endDate 2018-12-01T00:00:00Z
4 schema:keywords Bio-Rad
5 DNA
6 DNA barcodes
7 DNA fragment
8 Drug Therapy
9 GLC
10 Illumina
11 PCR amplification
12 PCR product
13 Peking University
14 XPS
15 bead
16 binding
17 biosystems
18 biotin
19 blood sample
20 buffer
21 centrifugation
22 chemical labeling
23 column
24 control group
25 cycle
26 drawing
27 epigenetic biomarkers
28 glucose
29 glucosyltransferases
30 instrument
31 library
32 locus
33 micro
34 min
35 nucleic acid
36 osteosarcoma
37 peripheral blood
38 plasma
39 processing
40 protocol
41 purified DNA
42 reaction mixture
43 room temperature
44 rotation
45 seal
46 sequencing
47 sequencing method
48 solution
49 streptavidin
50 technique
51 technology
52 wash
53 water
54 schema:name Indentifying Epigenetic Biomarkers From Peripheral Blood of Osteosarcoma Patients Based on hMe-Seal Technique
55 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03336554
56 schema:sdDatePublished 2019-03-07T15:27
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher Ne3dd9ec6f81b4de386e5a096401803cd
59 schema:sponsor https://www.grid.ac/institutes/grid.11135.37
60 https://www.grid.ac/institutes/grid.16753.36
61 https://www.grid.ac/institutes/grid.170205.1
62 https://www.grid.ac/institutes/grid.411634.5
63 schema:startDate 2017-09-01T00:00:00Z
64 schema:subjectOf sg:pub.10.1007/978-1-4419-0284-9_15
65 sg:pub.10.1007/s13277-013-0966-x
66 sg:pub.10.1038/nchem.2064
67 sg:pub.10.1038/srep17568
68 https://app.dimensions.ai/details/publication/pub.1077461573
69 https://doi.org/10.1002/cncr.27651
70 https://doi.org/10.1002/jso.23076
71 https://doi.org/10.1016/j.canep.2015.05.001
72 https://doi.org/10.1016/s1470-2045(16)30214-5
73 https://doi.org/10.1093/nar/gkh739
74 https://doi.org/10.1159/000448705
75 https://doi.org/10.1177/0300060514534643
76 schema:url https://clinicaltrials.gov/show/NCT03336554
77 sgo:license sg:explorer/license/
78 sgo:sdDataset clinical_trials
79 rdf:type schema:MedicalStudy
80 Ne3dd9ec6f81b4de386e5a096401803cd schema:name Springer Nature - SN SciGraph project
81 rdf:type schema:Organization
82 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
83 rdf:type schema:DefinedTerm
84 sg:pub.10.1007/978-1-4419-0284-9_15 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017083848
85 https://doi.org/10.1007/978-1-4419-0284-9_15
86 rdf:type schema:CreativeWork
87 sg:pub.10.1007/s13277-013-0966-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1004216767
88 https://doi.org/10.1007/s13277-013-0966-x
89 rdf:type schema:CreativeWork
90 sg:pub.10.1038/nchem.2064 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021457238
91 https://doi.org/10.1038/nchem.2064
92 rdf:type schema:CreativeWork
93 sg:pub.10.1038/srep17568 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010916831
94 https://doi.org/10.1038/srep17568
95 rdf:type schema:CreativeWork
96 https://app.dimensions.ai/details/publication/pub.1077461573 schema:CreativeWork
97 https://doi.org/10.1002/cncr.27651 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004665337
98 rdf:type schema:CreativeWork
99 https://doi.org/10.1002/jso.23076 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043913930
100 rdf:type schema:CreativeWork
101 https://doi.org/10.1016/j.canep.2015.05.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028431590
102 rdf:type schema:CreativeWork
103 https://doi.org/10.1016/s1470-2045(16)30214-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035951195
104 rdf:type schema:CreativeWork
105 https://doi.org/10.1093/nar/gkh739 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052677568
106 rdf:type schema:CreativeWork
107 https://doi.org/10.1159/000448705 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033830562
108 rdf:type schema:CreativeWork
109 https://doi.org/10.1177/0300060514534643 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016778774
110 rdf:type schema:CreativeWork
111 https://www.grid.ac/institutes/grid.11135.37 schema:Organization
112 https://www.grid.ac/institutes/grid.16753.36 schema:Organization
113 https://www.grid.ac/institutes/grid.170205.1 schema:Organization
114 https://www.grid.ac/institutes/grid.411634.5 schema:Organization
 




Preview window. Press ESC to close (or click here)


...